DSCSA 2024 Ten Count: Number 1 - Counterfeit Ozempic and the Ongoing Fight for Supply Chain Security

January 17, 2025

Ten Count Consulting reflects on 2024 with our list of top DSCSA moments and stories from 2024.

Number 1-

Counterfeit Ozempic and the Ongoing Fight for Supply Chain Security

In a year filled with significant milestones for the Drug Supply Chain Security Act (DSCSA), one story stands out as the most impactful and urgent: the rise of counterfeit Ozempic in global markets. Katherine Eban's powerful investigative piece in Vanity Fair, " Why Counterfeit Ozempic Is a Global-Growth Industry," uncovers the dangerous proliferation of fake versions of this life-changing medication. This exposé not only sheds light on the vulnerabilities in the pharmaceutical supply chain but also underscores exactly why the DSCSA exists—to protect patients from harmful and counterfeit drugs. This story was so compelling that it earned a spot in Apple News' top 12 most fascinating reads of 2024.

The surge in demand for Ozempic, primarily used to manage type 2 diabetes and increasingly sought after for weight loss, created a perfect storm. Supply shortages further fueled counterfeiters' efforts to introduce fake products into the supply chain. These counterfeit drugs, often containing incorrect dosages or harmful substances, pose serious health risks to unsuspecting patients. The consequences are not merely hypothetical—people's lives are being endangered by these fraudulent products.

This crisis highlights the critical importance of the DSCSA in securing the pharmaceutical supply chain. The DSCSA was designed to prevent, detect, and respond exactly to this type of threat. See our blog post: Can DSCSA Really Keep Patients Safe?. DSCSA requires interoperable exchange of serialized transaction data, ensuring that every product can be traced back to its source. The law mandates that trading partners verify they are authorized, which significantly reduces the chance of counterfeit drugs entering legitimate distribution channels.

Katherine Eban's investigative journalism has long been a catalyst for change in the pharmaceutical industry. Her groundbreaking book, Dangerous Doses, exposed systemic vulnerabilities in the drug supply chain years before the DSCSA was enacted. Her latest work on counterfeit Ozempic is a stark reminder that despite regulatory advancements, threats remain. Eban's continued efforts amplify the need for vigilance and full compliance with DSCSA.

At Ten Count Consulting, we recognize that this story epitomizes why DSCSA compliance is not just a regulatory obligation but a moral imperative. The rise of counterfeit Ozempic is a wake-up call to the industry: every stakeholder must prioritize supply chain security to protect patients. This is why we placed this story at #1 in our Ten Count of the most significant DSCSA moments and stories of 2024. It is a real-world example of how non-compliance and supply chain vulnerabilities can have devastating consequences.

Our mission has always been to support clients in understanding and implementing DSCSA requirements. Stories like this drive home the urgency of that mission. We are committed to helping our clients strengthen their systems to prevent counterfeit drugs from reaching patients.

The fight against counterfeit medications is far from over, but by bringing DSCSA into full operational effectiveness and ongoing industry vigilance, we can make significant strides in protecting public health. Let this story serve as a powerful reminder: compliance matters.